Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

Inclusion Criteria:

- Subjects must give a written, signed and dated informed consent

- Chronic plaque-type psoriasis present for at least 6 months before randomization

- Moderate to severe plaque psoriasis as defined at randomization by:

- PASI score of ≥12 and

- Body Surface Area (BSA) affected by plaque-type psoriasis ≥10% and

- IGA mod 2011 ≥3 (based on a scale of 0-4)

- Candidate for systemic therapy, defined as having psoriasis inadequately controlled
by:

- Topical treatment (including topical corticosteroids) and/or

- Phototherapy and/or

- Previous systemic therapy

Exclusion Criteria:

- Forms of psoriasis other than plaque psoriasis

- Drug-induced psoriasis

- Ongoing use of prohibited treatments

- Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A
or IL-17RA, or ustekinumab, or any therapies targeting IL-12 or IL-23

- Use of any other investigational drugs within 5 half-lives of the investigational
treatment before study drug initiation

- Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply